Scott J Diede

4PUBLICATIONS
30CO-AUTHORS
Neurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jan 27, 2026
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II).

Pablo Hernáiz Driever, Uwe R Kordes, Ines B Brecht

|Aug 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.

Jason A Chesney, Antoni Ribas, Georgina V Long

|Jul 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella

|Dec 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.

Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio

Pageof 1

Frequent Collaborators

3 joint publications

Georgina V Long

2 joint publications

Pier Francesco Ferrucci

1 joint publications

Paola Queirolo

1 joint publications

Paolo Antonio Ascierto